Get the Stockscreener App
1.56
8.43%
-0.16
Atai Life Sciences N V stock is traded at $1.56, with a volume of 1.75M.
It is down -8.43% in the last 24 hours and down -14.86% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
See More
Previous Close:
$1.72
Open:
$1.73
24h Volume:
1.75M
Relative Volume:
0.68
Market Cap:
$312.31M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-5.5714
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
-13.46%
1M Performance:
-14.86%
6M Performance:
+29.10%
1Y Performance:
-26.06%
1-Day Range:
$1.54
$1.73
1-Week Range:
$1.54
$1.87
52-Week Range:
$1.03
$2.85
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
WALLSTRASSE 16, BERLIN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.57 | 312.31M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.18 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance
Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com
atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK
Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio - Yahoo Finance
Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Atai Life Sciences Prices $55 Million Stock Offering -February 13, 2025 at 04:47 am EST - Marketscreener.com
ATAI Life Sciences Secures Massive $55M War Chest for Breakthrough Mental Health Treatments - StockTitan
atai Life Sciences Announces Pricing of Public Offering of Common Shares - Yahoo Finance
atai Life Sciences unveils $55M public offering to advance mental health treatments - Proactive Investors USA
atai Life Sciences Secures Major Funding: $55M Share Offering to Revolutionize Mental Health Treatment Pipeline - StockTitan
Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback (ATAI:NASDAQ) - Seeking Alpha
Evaluating ATAI’s financial ratios for a profitable investment - US Post News
Get in on ATAI Life Sciences N.V’s (ATAI) buy-in window today! - SETE News
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trialICYMI - Proactive Investors USA
ATAI Life Sciences N.V (NASDAQ: ATAI) Has Succeeded In Attracting Investors This Year, The Stock Is Up 59.40% Year-To-Date – Marketing Sentinel - Marketing Sentinel
atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe - Proactive financial news
ATAI’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
ATAI Life Sciences N.V (ATAI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Market Insights: ATAI Life Sciences N.V (ATAI)’s Notable Drop of -3.13, Closing at 1.55 - The Dwinnex
Best Penny Stocks to Watch in February 2025, Using Technical Analysis - Investopedia
atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout - Proactive Investors USA
Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges - Simply Wall St
ATAI Life Sciences supervisory board member resigns - MSN
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst (NASDAQ:ATAI) - Seeking Alpha
Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study - Marketscreener.com
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder - Yahoo Finance UK
atai Life Sciences unveils positive results from Beckley Psytech’s alcohol use disorder trial - Proactive Investors USA
Atai Life Sciences N.V. Announces Resignation of Michael Auerbach as Member of the Supervisory Board of Directors and Supervisory Board?s Compensation Committee - Marketscreener.com
ATAI Life Sciences Board Member Resignation and Changes - TipRanks
8th Annual Neuroscience Innovation Forum - goingpublic.de
Srinivas Rao Assumes the Role of Sole CEO of Atai Life Sciences N.V -January 10, 2025 at 07:00 am EST - Marketscreener.com
atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline - Proactive financial news
I: TechBio Weekly News - substack.com
US Penny Stocks To Consider In December 2024 - Simply Wall St
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors USA
Thiel-Backed Psychedelic Firm Atai to Buy Stake in Beckley - MSN
Optimizing atai Life Sciences’ Banking Structure to Drive Growth - Citigroup
Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com India
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St
RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up - Seeking Alpha
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):